Allogene's CAR-T Platform Poised for Inflection Point | Adil Ali, MD posted on the topic | LinkedIn If off-the-shelf CAR-T works, the economics of oncology will be rewritten - and Allogene Therapeutics is arguably closest to that inflection point. Cema-cel is already in the pivotal Phase 2 ALPHA3 f...

Si le #CAR_T 🧬 Cema-cel ( #ALLO_501A) fonctionne, l’économie de l’oncologie sera réécrite et #Allogene 🇺🇸 est sans doute la plus proche de ce point d’inflexion.

#ASH25 #Cellectis #ALPHA3 #LBCL
www.linkedin.com/posts/adilra...